Zizhuo Tu

- BD: screened over 2000 in-pipeline & in-market assets across 9 diseases from the database. Conducted systematic research on disease unmet needs, mechanisms of activation, molecule designs and clinical data of targeted assets and summarized an asset short list of 30+ products. Assisted in assessment of BD feasibility by evaluating scientific and medical value, commercialization potential, IP exclusivity and manufacturing process. - New product planing: participated in the planing of 2 innovative drugs for asthma and SLE in China. Conducted in-depth research on disease pathology and clinical data of the products. Provided scientific and medical advice for the team.

- BD: participated in BD projects involving 3 candidate assets for lupus nephritis and CKD, interpreted the pathophysiology of diseases and mechanism and clinical evidence of the products, helped the team to evaluate BD feasibility. - New product launching: was deeply involved in the launching of Forxiga® (dapagliflozin) for CKD indication in China. Assisted in building of the medical story line and design of promoting materials.

- Engaged in innovative programs including iHospital and MMC, associated with external collaborators on distribution of trial devices.

- Collaborated with physicians, investigated the role of post-translational modifications in diabetic platelets.

- Dissertation title: Effect and mechanism of GSDMD-dependent pyroptosis on acute myocardial infarction. - Honor: 2022 National Scholarship for Doctoral Students (RMB 30,000)